Barbara K. Finck - Dec 31, 2022 Form 5 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
5
Date filed
2/14/2023, 04:53 PM
Previous filing
Jun 2, 2022
Next filing
Feb 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Buy) Award +37.1K 37.1K May 19, 2022 Common Stock 37.1K $0.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Barbara K. Finck is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest in 44 equal monthly installments beginning on June 8, 2021.
F2 This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company.